Launching a consumer healthtech product for a global pharma company in Southeast Asia

Context

A top-five global pharmaceutical company had been trying for two years to launch a consumer-facing digital health product across Southeast Asia. The product would sit adjacent to their existing pharmaceutical franchise: a patient-facing app that handled symptom triage, connected the user to a licensed teleconsultation provider, dispensed prescriptions through partnered pharmacies, and closed the loop with adherence and outcomes tracking.

The strategic case was large. Southeast Asia has over 600 million people, rising out-of-pocket healthcare spend, insufficient primary-care capacity, and regulatory frameworks that were finally opening to digital health. The pharma company had the brand, the relationships, the regulatory muscle, and the capital. What they did not have was an operating model.

Two prior attempts had stalled. The first, run as an internal innovation project, produced a slide deck and a stalled pilot. The second, contracted to a global management consultancy, produced a beautifully-written 340-page strategy document and a roadmap that would have taken three years and $180M to execute. Neither had put product in front of a patient.

We were brought in not to write another deck, but to ship.

Moved Fast

Week one, we killed the 340-page document. Not because it was wrong — parts of it were excellent — but because the company was using its length as an excuse not to decide. We extracted the six decisions that actually mattered (which market first, which teleconsultation partner, which pharmacy stack, which payer integration, which regulatory pathway, which localisation depth) and gave the steering committee 72 hours to decide each one. All six closed inside two weeks.

Market one was Indonesia. The Indonesian regulatory pathway was the most open and the pharma company's existing relationships there were the strongest. We stood up a dedicated cross-functional pod of nine — three from the pharma company, three from the teleconsultation partner we had helped them select, two from the local payer partner, and one from us — with a single mandate: get a minimum-viable consumer app into the App Store and Play Store in twenty weeks.

The pod shipped it in nineteen. Five months from scope-lock to live product, with a licensed teleconsultation backend, a pharmacy fulfilment rail across 1,400 outlets, insurance payer integration with two of the country's three largest private health insurers, and an AI-native intake flow that triaged symptoms, routed the patient to the right specialist, and generated a structured note for the downstream physician before the consultation even started.

Failed Forward

The Vietnam launch almost broke the engagement.

The Indonesian playbook was tempting to copy. The market looked similar on the surface — large population, growing digital economy, regulatory opening. But Vietnam's healthcare payer structure is fundamentally different. Public insurance covers a much higher share of primary care, and the private payers we would have partnered with in Indonesia are functionally absent from the segment the product was targeting.

We spent six weeks trying to force-fit the Indonesian model onto Vietnam. We lost a launch quarter. The correction, when it came, was to treat Vietnam as a fundamentally different product — same brand, same app shell, but a completely different partnership stack built around the public insurance pathway and a direct-to-consumer subscription layer that bypassed the payer question entirely.

The model we arrived at was stronger than what we would have shipped in a month. But it took four months instead of one. The lesson — which is now codified into B3n's multi-market engagement playbook — is that cross-market scaling in regulated industries is never about replicating the playbook. It is about replicating the method. Every market gets a fresh diagnostic, even if eighty percent of the answer looks the same.

Built

By engagement end, the product was live in Indonesia, Vietnam, and the Philippines. Three markets. Three partnership stacks. One shared product platform. One shared data layer. One shared operating model — with local adaptations codified rather than argued over.

Specifically:

• A consumer app handling symptom triage, teleconsultation booking, prescription fulfilment, and care continuity — with an AI-native intake layer that meaningfully compressed the average consultation length while improving diagnostic completeness.
• A provider-facing dashboard that let physicians manage caseloads, review AI-generated pre-consultation notes, and close consultations with structured documentation.
• Three regulatory pathways navigated with local counsel and on-the-ground regulatory affairs partners, resulting in clean operating permits in each market.
• Partnership rails across licensed teleconsultation providers, 3,200+ partnered pharmacies, and six insurance payers (combined).
• A localised operating pod in each market, staffed by a mix of pharma company employees, local partners, and specialised B3n-sourced operators, fully handed off by engagement end.

Compounds

The numbers matter, and they are large. Direct revenue from the three launched markets exceeded internal plan by 34 percent in the first four operational quarters. Indirect value — from the pharma company's cross-sell into the user base, from the adherence data flowing back into their existing franchise, and from the strategic optionality of now owning the patient relationship rather than renting it through prescriptions — was modelled internally at over $1B in five-year NPV by the company's own finance team. The company treats the number as confidential; we do not.

The deeper compound is organisational. The pharma company, which had spent two years unable to ship a consumer product, now has an operating model for consumer healthtech that travels. They have extended the platform to two additional markets since we handed off, without us. That is the test. The work compounds because the capacity to do the work is now theirs — not ours.